Study

Bryan Johnson announces a new Blueprint creatine batch

Bryan Johnson

N=1 PUBLIC PRODUCT AND SUPPLY UPDATE; NO CLINICAL STUDY 2026

NEW PRODUCT DROP / CONTROVERSY: Johnson says a new batch of Blueprint creatine came off the line after a reported $630,000 shipment theft; no clinical result or product test is reported.

DesignN=1 PUBLIC PRODUCT AND SUPPLY UPDATE; NO CLINICAL STUDY
TierTier 3, Ingredient RCT (matching dose)
Year2026
JournalSelf-published — x.com/bryan_johnson
N1
PublishedSep 18, 2026
Added to NO1GEVITYSep 23, 2026

On 18 September 2026, Bryan Johnson posted that $630,000 of “elite Blueprint creatine” had been stolen earlier in the year after a driver used a fake ID to take the delivery truck. He said the company had come close to finding the person and that a new batch had just come off the production line. The post is a supply and product-availability update, not a creatine experiment. It gives no batch number, certificate of analysis, manufacturing test, quantity available, release date, price change, adverse-event information or evidence that the product differs from earlier batches. The theft allegation is Johnson’s own account; this record does not add unverified details about a suspect. A new production batch does not show that Blueprint creatine improves strength, cognition, healthspan or longevity. The post also does not report whether the product is available to consumers or whether the new batch underwent independent testing. It is included because the task tracks product drops and public protocol-adjacent updates. The evidence boundary is simple: a new batch was announced, but no clinical or comparative product result was supplied.

A new batch came off the line; no scientific conclusion or clinical outcome is reported.
Critic notes

No relevant critic or new human RCT/meta-analysis tested this product update. The announcement does not support a creatine evidence-grade change.

Read the source

Cited by

2 encyclopedia entries reference this study.